AstraZeneca, Gilead merger doubted by Wall Street analysts
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- Wall St slides as oil tops $100, yields hit 2023 high; Apple down before Ternus' first launch event as CEO
- Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
- Oil nears $100 as fresh Middle East strikes raise supply risks
- How big a risk are rates to the AI boom?
- 3 reasons why S&P 500 may drop up to 10% in the near term: RBC
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
AstraZeneca (AZN) PT Raised to $60 at Cowen
June 10, 2020 8:45 AM EDTCowen analyst Steve Scala raised the price target on AstraZeneca (NYSE: AZN) to $60.00 (from $55.00) while maintaining an Outperform rating after updating the model following recent news including ASCO presentations, additional roxadustat data, and reports that AZN had contemplated a large-scale business... More
AstraZeneca (AZN) CEO Soriot Said to Have Called Gilead (GILD) CEO on May 9, Proposed Exploring Merger to O'Day on Call - Bloomberg
June 8, 2020 5:04 PM EDTAstraZeneca (NYSE: AZN) CEO Soriot Said to Have Called Gilead (NASDAQ: GILD) CEO on May 9, Proposed Exploring Merger to O'Day on Call - Bloomberg
... MoreGilead Sciences (GILD) Worth $120+ in Rumored Takeover - Piper Sandler
June 8, 2020 9:49 AM EDTPiper Sandler analyst Tyler Van Buren reiterated an Overweight rating and $90.00 price target on Gilead Sciences (NASDAQ: GILD) following rumor of a potential deal with AstraZeneca (NYSE: AZN). Van Buren sees Gilead worth $120+ per share in a deal.
The analyst commented, "The... More
